Alkermes (ALKS) Gains from Sales and Divestitures (2012 - 2025)
Alkermes (ALKS) reported Gains from Sales and Divestitures of $469513.0 for Q4 2025, down 79.01% year-over-year from $2.2 million in Q4 2024, and down 79.01% quarter-over-quarter from $2.2 million in Q4 2024.
Alkermes (ALKS) Gains from Sales and Divestitures (2012 - 2025) Analysis & Trends
Alkermes (ALKS) has 14 years of Gains from Sales and Divestitures data on file, last reported at $469513.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $469513.0, down 79.01% year-over-year; the trailing twelve-month figure through Dec 2025 was $469513.0 (down 79.01% YoY), and the FY2025 annual result was $469513.0, down 79.01% from the prior year.
- Gains from Sales and Divestitures retreated to $469513.0 in Q4 2025 per ALKS's latest filing, from $2.2 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $2.2 million in Q4 2024 and troughed at $252375.0 in Q4 2023.
- A 5-year average of $1.4 million and a median of $1.9 million in 2021 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures slumped 87.7% in 2023, then jumped 786.5% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $1.9 million in 2021, then advanced by 8.63% to $2.1 million in 2022, then tumbled by 87.7% to $252375.0 in 2023, then soared by 786.5% to $2.2 million in 2024, then plunged by 79.01% to $469513.0 in 2025.
- Business Quant data shows ALKS's Gains from Sales and Divestitures at $469513.0 in Q4 2025, $2.2 million in Q4 2024, and $252375.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 469,513.00 |
| Dec 31, 2025 | 469,513.00 |
| Dec 31, 2024 | 2.24 Mn |
| Dec 31, 2024 | 2.24 Mn |
| Dec 31, 2023 | 252,375.00 |
| Dec 31, 2023 | 252,375.00 |
| Dec 31, 2022 | 2.05 Mn |
| Dec 31, 2022 | 2.05 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Dec 31, 2020 | 1.10 Mn |
| Dec 31, 2020 | 1.10 Mn |
| Dec 31, 2019 | 1,614.00 |
| Dec 31, 2019 | 1,614.00 |
| Dec 31, 2018 | 723,473.00 |
| Dec 31, 2018 | 723,473.00 |
| Dec 31, 2017 | 730,085.00 |
| Dec 31, 2017 | 730,085.00 |
| Dec 31, 2016 | 270,409.00 |
| Dec 31, 2016 | 270,409.00 |